Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter Reporting

AIML · Price

Executive Summary

  • NeuralCloud Solutions (a subsidiary of AI/ML Innovations) entered a non‑binding agreement with Movesense to pilot the deployment of its MaxYield™ ECG signal‑processing platform and CardioYield™ reporting software in third‑party health systems and affiliated clinics.
  • The pilot will use Movesense’s medically certified wearable sensors as the data acquisition layer, with NeuralCloud providing AI‑driven analysis and visualization, aiming to increase ECG/Holter reporting capacity and standardize outputs without adding clinical workload.
  • Successful validation could lead to a broader commercial rollout, subject to definitive agreements, regulatory approvals, and pilot results.

Key Details

  • Agreement: Non‑binding collaboration agreement signed on February 11, 2026 between NeuralCloud (AI/ML Innovations) and Movesense.
  • Pilot Scope: Deployment of MaxYield™ ECG signal‑processing platform and CardioYield™ visualization/reporting software via an existing Movesense client into a third‑party health system and its clinics.
  • Objectives:
  • Evaluate increased ECG analysis capacity and reporting consistency.
  • Enhance clinical throughput and standardize reporting outputs.
  • Validate integration of AI‑powered analysis with wearable hardware in real‑world outpatient, ambulatory, and Holter‑style monitoring environments.
  • Potential Commercialization: Pilot results will inform a possible commercial rollout; any future agreements will be definitive and subject to regulatory considerations.
  • Quotes:
  • Paul Duffy, Executive Chairman & CEO, AI/ML Innovations: “This expansion builds logically on the framework we announced in January… advancing toward practical, scalable solutions that address growing monitoring demands in ambulatory care.”
  • Jussi Kaasinen, CEO, Movesense: “We see continued value in exploring how NeuralCloud's signal processing and reporting platforms can enhance the utility of our scalable ECG sensing technology.”
  • Company Backgrounds:
  • Movesense – Finnish ISO 13485‑certified manufacturer of medical‑grade wearable sensors (single‑lead ECG, HR, HRV, motion).
  • AI/ML Innovations – Global AI/ML company focused on digital health platforms that convert biometric data into actionable clinical insights.

Notable Quotes

  • “By continuing to align NeuralCloud's software platforms with Movesense's device ecosystem, we are advancing toward practical, scalable solutions that address growing monitoring demands in ambulatory care.” – Paul Duffy, Executive Chairman & CEO, AI/ML Innovations
  • “This expanded collaboration allows us to further assess integration, performance, and operational fit within healthcare workflows.” – Jussi Kaasinen, CEO, Movesense
Read the original news release →

More from AI-ML Innovations Inc.